These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34281850)

  • 41. Value of prostate-specific antigen measurements in predicting lymph node involvement in prostatic cancer.
    Arai Y; Yoshiki T; Yamabe H; Yoshida O
    Urol Int; 1990; 45(6):356-60. PubMed ID: 1705062
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
    Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
    Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer.
    Sung MT; Lin H; Koch MO; Davidson DD; Cheng L
    Am J Surg Pathol; 2007 Feb; 31(2):311-8. PubMed ID: 17255778
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy.
    Zhang M; Guan J; Huo YL; Song YS; Chen LZ
    Asian J Androl; 2019; 21(4):387-392. PubMed ID: 30860083
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term Results of External Beam Radiotherapy for Prostate Cancer with Prostate-specific Antigen of More Than 50 ng/ml and Without Evidence of Lymph Node or Distant Metastasis.
    Umezawa R; Inaba K; Nakamura S; Wakita A; Okamoto H; Shima S; Tsuchida K; Kashihara T; Kobayashi K; Harada K; Takahashi K; Murakami N; Ito Y; Igaki H; Jingu K; Itami J
    Anticancer Res; 2018 Apr; 38(4):2303-2309. PubMed ID: 29599353
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of Radiation Facility Volume and Survival in Men With Lymph Node-Positive Prostate Cancer Treated With Radiation and Androgen Deprivation Therapy.
    Patel SA; Goyal S; Liu Y; Moghanaki D; Patel PR; Hanasoge S; Dhere VR; Shelton JW; Godette KD; Jani AB; Hershatter B; Fischer-Valuck BW
    JAMA Netw Open; 2020 Dec; 3(12):e2025143. PubMed ID: 33301015
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value of lymph node metastasis in patients with T1-stage colorectal cancer from multiple centers in China.
    Sun ZQ; Ma S; Zhou QB; Yang SX; Chang Y; Zeng XY; Ren WG; Han FH; Xie X; Zeng FY; Sun XT; Wang GX; Li Z; Zhang ZY; Song JM; Liu JB; Yuan WT
    World J Gastroenterol; 2017 Dec; 23(48):8582-8590. PubMed ID: 29358866
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lactate dehydrogenase and creatine kinase as poor prognostic factors in lung cancer: A retrospective observational study.
    Liu L; He Y; Ge G; Li L; Zhou P; Zhu Y; Tang H; Huang Y; Li W; Zhang L
    PLoS One; 2017; 12(8):e0182168. PubMed ID: 28767733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is preoperative serum lactate dehydrogenase useful in predicting the outcomes of patients with upper tract urothelial carcinoma?
    Tan P; Chen J; Xie N; Xu H; Ai J; Xu H; Liu L; Yang L; Wei Q
    Cancer Med; 2018 Oct; 7(10):5096-5106. PubMed ID: 30151961
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy.
    Wang Y; Yin W; Wang Z; Huang J; Pan J; Zhu Y; Xu F; Shao X; Sha J; Cai Y; Liu Q; Dong B; Xue W; Huang Y
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):209-15. PubMed ID: 26951714
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study.
    Rusthoven CG; Carlson JA; Waxweiler TV; Raben D; Dewitt PE; Crawford ED; Maroni PD; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1064-73. PubMed ID: 24661660
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum fibrinogen levels are positively correlated with advanced tumor stage and poor survival in patients with gastric cancer undergoing gastrectomy: a large cohort retrospective study.
    Yu X; Hu F; Yao Q; Li C; Zhang H; Xue Y
    BMC Cancer; 2016 Jul; 16():480. PubMed ID: 27418164
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
    Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
    Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
    Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy.
    Resende Salgado L; Rhome R; Oh W; Stone N; Stock R
    Brachytherapy; 2018; 17(6):874-881. PubMed ID: 30061057
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum lactate dehydrogenase in combination with free-to-total serum prostate specific antigen ratio for diagnosis of prostate cancer.
    Santotoribio JD; Cañavate-Solano C; Garcia-de la Torre A; Arce-Matute F; Perez-Ramos S
    Clin Lab; 2014; 60(6):1055-8. PubMed ID: 25016713
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic value of systemic inflammatory factors NLR, LMR, PLR and LDH in penile cancer.
    Hu C; Bai Y; Li J; Zhang G; Yang L; Bi C; Zhao B; Yang Y; Li R; Wu H; Wang Q; Qin Y
    BMC Urol; 2020 May; 20(1):57. PubMed ID: 32460817
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer.
    Mori K; Kimura T; Onuma H; Kimura S; Yamamoto T; Sasaki H; Miki J; Miki K; Egawa S
    Prostate; 2017 Jul; 77(10):1144-1150. PubMed ID: 28557065
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer.
    Wang YJ; Huang CY; Hou WH; Wang CC; Lan KH; Chen CH; Yu HJ; Lai MK; Cheng AL; Liu SP; Pu YS; Cheng JC
    World J Surg Oncol; 2015 Nov; 13():312. PubMed ID: 26545980
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes.
    Lee DS; Park KR; Kim SJ; Chung MJ; Lee YH; Chang JH; Kang JH; Hong SH; Kim MS; Kim YS
    Tumour Biol; 2016 Jan; 37(1):619-25. PubMed ID: 26240025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.